Acrivon Therapeutics

Update in progress

ACRV (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on oncology medicines tailored to tumors predicted to respond to each drug, using its generative phosphoproteomics platform. Through AP3, it develops OncoSignature companion diagnostics to identify patients likely to benefit from its therapies. Lead candidate ACR-368 inhibits CHK1/CHK2 for endometrial and platinum-resistant ovarian cancer and certain squamous cell carcinomas. They also develop ACR-2316, a dual WEE1/PKMYT1 inhibitor, plus preclinical programs. Founded 2018, based in Watertown, MA.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.07; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive